Search 

Black Belt is a preclinical stage biotech company focused on the stress response in the tumour microenvironment. Black Belt targets cancers cells stress-associated survival mechanisms and reverts stress-induced immune cell dysfunction. We have built a diversified pipeline of first-in-class small molecule programmes as well as a proprietary target discovery and validation platform. The company is working with the acadmic KOLs in the stress response field. Black Belt has an experienced team of drug developers and was created as a spin-off from Tusk Therapeutics which was acquired by Roche in September 2018 for 655 million EUR.

Oxford based Biotech seeking partners to take forward our NCE assets in behavioural brain disease to complete IND enabling and move into clinic. We are open to licensing and funding/collaboration discussions. Orexin 1 antagonist in Addiction. Atypical DAT inhibitor in Fatigue (with potential in Narcolepsy).

OxStem is a small molecule discovery company targeting innate regeneration and repair.

OxStem was founded by three eminent Oxford University professors with the goal of using small molecules to activate or re-program tissue-resident (endogenous) stem and progenitor cells. The founders were joined by thirteen world-leading Oxford scientists and physicians with respective expertise in OxStem's five programs: haematological malignancies, neurodegenerative diseases, retinal diseases, cardiovascular disease and diabetes.